| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Fursultiamine is a vitamin B1 derivative and a medication used for therapy of thiamine deficiency. It’s phosphorylated metabolites may be administered as multivitamin preparations. Fursultiamine has been identified as a drug candidate against prostate cancer from the aspect of somatic cell reprogramming and may be useful as a therapeutic tool in number of human neurological diseases.
| References | |
|---|---|
| Additional Infomation |
Fursultiamine is a member of pyrimidines.
Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative. Fursultiamine is a nutritional supplement and vitamin B1 derivative, with potential antineoplastic activity. Upon oral administration, fursultiamine inhibits the expressions of octamer-binding transcription factor 4 (OCT-4), SRY (sex determining region Y)-box 2 (SOX-2), and Nanog homeobox (NANOG) in cancer stem cells (CSCs). This may inhibit the proliferation of CSCs thereby preventing tumor cell growth. In addition, fursultiamine inhibits the expression of ATP-binding cassette (ABC) transporters subfamily B member 1 (ABCB1) and subfamily G member 2 (ABCG2) in cancer CSCs, which may abrogate resistance to chemo- and radiotherapy in CSCs. CSCs promote tumor initiation, progression and metastasis; they play a key role in cancer recurrence and resistance to chemotherapy and radiation. Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. |
| Molecular Formula |
C17H26N4O3S2
|
|---|---|
| Molecular Weight |
398.5433
|
| Exact Mass |
398.144
|
| CAS # |
804-30-8
|
| Related CAS # |
67-03-8 ( Thiamine HCl; Vitamin B1 HCl salt); 16816-67-4 ( Pantethine, a derivative of vitamin B5); 29883-15-6 (Vitamin B17 derivative); 22457-89-2 (synthetic vitamin B1; BRN-0771326; BTMP; CB-8088; Berdi; Betivina; Biotamin; Benfotiamine; S-benzoylthiamine O-monophosphate); 59-30-3 (Folic acid); 13870-90-1 [Coenzyme B12 (adenosylcobalamin; AdoCbl)]; 68-19-9 (vitamin B 12 related); 13422-55-4 (Mecobalamin, an analog of Vitamin B12); 80037-86-1 (Succinylacetone pyrrole, an inhibitor of vitamin B12 biosynthesis)
|
| PubChem CID |
3002119
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
652.3±55.0 °C at 760 mmHg
|
| Melting Point |
130-136ºC (decompos.)
|
| Flash Point |
348.3±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.626
|
| LogP |
2.35
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
26
|
| Complexity |
481
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=CN(CC1C(N)=NC(C)=NC=1)C(C)=C(CCO)SSCC1CCCO1
|
| InChi Key |
JTLXCMOFVBXEKD-FOWTUZBSSA-N
|
| InChi Code |
InChI=1S/C17H26N4O3S2/c1-12(16(5-6-22)26-25-10-15-4-3-7-24-15)21(11-23)9-14-8-19-13(2)20-17(14)18/h8,11,15,22H,3-7,9-10H2,1-2H3,(H2,18,19,20)/b16-12+
|
| Chemical Name |
(E)-N-((4-amino-2-methylpyrimidin-5-yl)methyl)-N-(5-hydroxy-3-(((tetrahydrofuran-2-yl)methyl)disulfanyl)pent-2-en-2-yl)formamide
|
| Synonyms |
Fursultiamine; Judolor; Linamin; EINECS 212-357-1; Tetrahydrofurfuryl thiamine disulfide; TTFD; Adventan, Alinamin-F, Benlipoid, Bevitol Lipophil, Judolor, Lipothiamin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~106.7 mg/mL (~267.73 mM)
H2O : ≥ 6.67 mg/mL (~16.74 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5092 mL | 12.5458 mL | 25.0916 mL | |
| 5 mM | 0.5018 mL | 2.5092 mL | 5.0183 mL | |
| 10 mM | 0.2509 mL | 1.2546 mL | 2.5092 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA